Reference health
Surgical outcomes in patients with cutaneous malignant melanoma in Europe – a systematic literature review
48/48 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 48 checked references that resolve
resolves10.1016/j.ejca.2012.12.027
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
resolves10.1016/S1470-2045(13)70546-1
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study
resolves10.1111/j.1365-2133.2004.05708.x
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
resolves10.1002/1097-0142(19950515)75:10<2499::AID-CNCR2820751016>3.0.CO;2-8
Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of clark's level for prognostic classification
resolves10.1002/ijc.23543
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression
resolves10.1002/cncr.11196
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma
resolves10.1093/annonc/mdv297
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
resolves10.1016/S1470-2045(15)70122-1
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
resolves10.1016/j.ejca.2012.06.013
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012
resolves10.1016/j.ijsu.2010.02.007
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
resolves10.1245/s10434-007-9606-2
Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Case-Control Study
resolves10.1016/j.ejso.2005.09.009
Non-compliance with the re-excision guidelines for cutaneous melanoma in The Netherlands does not influence survival
resolves10.1016/S0140-6736(11)61546-8
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
resolves10.1159/000300047
The Outcome of Patients with Melanoma Is Not Associated with the Time Point of Lymphatic Mapping with Respect to Excisional Biopsy of the Primary Tumor
resolves10.1245/s10434-008-9965-3
The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3)
resolves10.1245/s10434-006-9302-7
Non-Radical Diagnostic Biopsies Do Not Negatively Influence Melanoma Patient Survival
resolves10.1111/j.1365-2133.2004.06050.x
Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma
resolves10.1111/j.1365-2133.2004.05849.x
A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision
resolves10.1245/s10434-009-0780-2
Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement
resolves10.1016/j.ejso.2012.12.014
The analysis of the outcomes and factors related to iliac–obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases
resolves10.1245/s10434-010-1318-3
Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up
resolves10.1016/j.ejca.2005.10.012
In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection
resolves10.1016/j.ejca.2004.11.019
Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas
resolves10.1111/j.1365-4632.2012.05706.x
A 10‐year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long‐term follow‐up
resolves10.1308/147870811X13137608455019
Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM
resolves10.1002/cncr.24852
Early (sentinel lymph node biopsy‐guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases
resolves10.1111/j.1365-2133.2005.06941.x
Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients
resolves10.1002/bjs.8878
Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection
resolves10.1002/bjs.5814
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma
resolves10.1002/ijc.22707
Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: A follow‐up study of 148 patients
resolves10.1016/S1470-2045(15)00482-9
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial
resolves10.5772/53625
Sentinel Lymph Node Biopsy for Melanoma and Surgical Approach to Lymph Node Metastasis
resolves10.1002/bjs.4692
High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma
resolves10.1016/S1470-2045(16)00141-8
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
resolves10.1200/JCO.2009.23.4518
Therapeutic Effect of Sentinel Lymph Node Biopsy in Melanoma Remains an Open Question
resolves10.1056/NEJMoa1310460
Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
resolves10.1111/bjd.13675
No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report
resolves10.1111/bjd.13676
Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management
resolves10.1200/JCO.2001.19.16.3622
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
resolves10.1200/JCO.2001.19.16.3635
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
The 4 references without a DOI — listed, not checked
no DOI — not checkedSkin cancer and melanoma awareness campaign
no DOI — not checkedEuropean Medicines Agency.Keytruda (pembrolizumab). EMA/CHMP/298313/2015. Committee for Medicinal Products for Human Use (CHMP).2015.
no DOI — not checkedEuropean Medicines Agency.Opdivo (nivolumab). Summary of Opinion. EMA/CHMP/76686/2015. Committee for Medicinal Products for Human Use (CHMP).2015.
no DOI — not checkedSentinel lymph node biopsy or nodal observation in melanoma: study of an Italian series
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/jdv.13950"><img src="https://citestamp.com/citestamped/10.1111/jdv.13950/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/jdv.13950)